tetano
Editor, Senior Moderator
Vaccine. 2013 May 21. pii: S0264-410X(13)00601-4. doi: 10.1016/j.vaccine.2013.05.023. [Epub ahead of print]
Virus-like particle vaccine protects against H3N2 canine influenza virus in dog.
Lee DH, Bae SW, Park JK, Kwon JH, Yuk SS, Song JM, Kang SM, Kwon YK, Kim HY, Song CS.
Source
Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea.
Abstract
In the present study, virus-like particles (VLPs) were evaluated as a candidate veterinary vaccine against canine influenza virus (CIV) subtype H3N2. Specific pathogen-free (SPF) beagle dogs received a single injection of a VLP vaccine containing hemagglutinin (HA) and M1 protein of CIV H3N2 (H3 HA VLP). The vaccine was tested at 3 different doses with an adjuvant and 1 dose without an adjuvant. To evaluate the immunogenicity and protective efficacy of the H3 HA VLP vaccine, we performed hemagglutination inhibition tests to determine serological immune responses and conducted challenge studies using SPF beagle dogs. The addition of Montanide ISA 25 adjuvant significantly increased the immunogenicity of the H3 HA VLP vaccine. The experimental infection study showed that a single dose of H3 HA VLP vaccine induced protection against wild-type virus challenge in dogs. These results provide support for continued development of the VLP as an animal vaccine against influenza virus.
Copyright ? 2013. Published by Elsevier Ltd.
PMID:
23707159
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23707159
Virus-like particle vaccine protects against H3N2 canine influenza virus in dog.
Lee DH, Bae SW, Park JK, Kwon JH, Yuk SS, Song JM, Kang SM, Kwon YK, Kim HY, Song CS.
Source
Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea.
Abstract
In the present study, virus-like particles (VLPs) were evaluated as a candidate veterinary vaccine against canine influenza virus (CIV) subtype H3N2. Specific pathogen-free (SPF) beagle dogs received a single injection of a VLP vaccine containing hemagglutinin (HA) and M1 protein of CIV H3N2 (H3 HA VLP). The vaccine was tested at 3 different doses with an adjuvant and 1 dose without an adjuvant. To evaluate the immunogenicity and protective efficacy of the H3 HA VLP vaccine, we performed hemagglutination inhibition tests to determine serological immune responses and conducted challenge studies using SPF beagle dogs. The addition of Montanide ISA 25 adjuvant significantly increased the immunogenicity of the H3 HA VLP vaccine. The experimental infection study showed that a single dose of H3 HA VLP vaccine induced protection against wild-type virus challenge in dogs. These results provide support for continued development of the VLP as an animal vaccine against influenza virus.
Copyright ? 2013. Published by Elsevier Ltd.
PMID:
23707159
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23707159